Allarity Therapeutics Inc.

About Allarity Therapeutics Inc.

Allarity Therapeutics is a clinical-stage precision medicine company focused on advancing stenoparib, an orally available small molecule inhibitor for patients with advanced recurrent ovarian cancer. The company leverages its proprietary Drug Response Predictor (DRP®) technology to enhance patient selection and improve clinical outcomes, committed to personalized cancer care. Publicly traded on NASDAQ under the ticker ALLR, Allarity aims to improve decision-making and patient outcomes in cancer treatment.

Products & Services

Stenoparib:An orally available small molecule inhibitor targeting DNA damage repair enzymes (PARP) and cell division/growth enzymes (Tankyrase) in tumor cells. It shows promise in ovarian and pancreatic cancers, with FDA Fast Track designation for advanced ovarian cancer, and potential for combination therapies due to low myelotoxicity.

Drug Response Predictor (DRP®) Technology:A first-in-class diagnostic platform that models human tumor biology to predict patient response to specific drugs, enabling personalized cancer treatment. It is clinically validated and supported by peer-reviewed publications.

DRP® Cancer Tests:Tests utilizing DRP® technology to assist in predicting drug response for cancer patients.

Gene Expression Profiling:Services for clinical research focused on drug response prediction using gene expression data.

Specialties

Precision Medicine Personalized Cancer Care Drug Response Prediction (DRP®) Technology Oncology Therapeutics PARP Inhibitors Tankyrase Inhibition

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Non-Convertible Debt T: - FT: Non-Convertible Debt	A: 20000000 MR: - FA: $20 million FAN: 20000000	D: 2026-03-06 FD: 2026-03-06	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 11000000 MR: - FA: approximately $11 million FAN: 11000000	D: 2023-07-06 FD: 2023-07-06	1 investors
3	RT: Public Offering T: - FT: Public Offering	A: 7500000 MR: - FA: 7.5 Million FAN: 7500000	D: 2023-04-19 FD: 2023-04-19	-

Non-Convertible Debt Latest

2026-03-06

$20.0M

1 investor (Pro only)

Public Offering 2023-07-06

$11.0M

Public Offering 2023-04-19

$7.5M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel D. Von Hoff

Physician in Chief and Distinguished Professor

U

Ursula A. Matulonis

Chief and Director of the Division of Gynecologic Oncology and Professor of Medicine

J

Joyce A. O'Shaughnessy

Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research

M

Mansoor Raza Mirza

Chief Oncologist

R

Roberto Pili

Associate Dean for Cancer Research and Integrative Oncology, Professor and Chief of the Division of Hematology/Oncology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

J

Jerry McLaughlin

Chairman, Independent Board Member

View 9 more team members with Pro

Unlock Full Team Directory

Recent News